20
MAY
2011

Northwest Biotherapeutics To Present At American Society Of Cell And Gene Therapy

Posted By :
Comments : Off
Talk will highlight early clinical data, and the phase II clinical trial design Bethesda, Maryland, May 20, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chief Technical Officer, Dr. Marnix Bosch, will give a presentation on “Autologous Dendritic Cells for Glioblastoma” on Saturday, on May 21, at 1:45 pm at the 14thAnnual Meeting of the American Society of Cell and Gene Therapy in Seattle, WA. Dr....
Read More
18
MAY
2011

Northwest Biotherapeutics And The Fraunhofer Institute For Cell Therapy And Immunology Are Partnering For Clinical Trials And Compassionate Use Cases in Europe

Posted By :
Comments : Off
Bethesda, Maryland, May 18, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that it is partnering with Fraunhofer for production of DCVax®-L for brain cancer, for clinical trials and compassionate use cases in Europe. Fraunhofer is the largest applied research foundation in Europe, with a staff of more than 18,000 scientists, engineers, business personnel and others dedicated to practical applications and...
Read More
03
MAY
2011

Northwest Biotherapeutics’ Ongoing Brain Cancer Trial Recruiting Additional Patients At Four Medical Centers Across US

Posted By :
Comments : Off
Number Of Centers Further Expected To More Than Double This Quarter Bethesda, Maryland, May 3, 2011 — Northwest Biotherapeutics (OTC.BB:NWBO) today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the...
Read More
16
MAR
2011

Northwest Biotherapeutics Addresses Recent Market Activity

Posted By :
Comments : Off
Bethesda, Maryland, March 16, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO). Taking note of the recent unusual activity in the Company’s stock, Northwest Biotherapeutics (NWBT) commented today that it is not aware of any basis relating to the Company or its products or programs. The Company is continuing to move forward with the trial-related activities for its large, 240-patient clinical trial for GBM brain cancer. The...
Read More
14
FEB
2011

Northwest Biotherapeutics To Present At BIO CEO & Investor Conference

Posted By :
Comments : Off
Highlights Include Clinical and Corporate Updates, Striking Long-Term Data, and Lack of Toxicity, Low Cost and Simplicity of DCVax® Therapeutic Vaccines Bethesda, Maryland, February 14, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization’s BIO CEO &...
Read More